Advertisement

Viral Hepatitis

  • C. Wendy SpearmanEmail author
  • Ronalda de Lacy
  • Elizabeth Goddard
Chapter
  • 357 Downloads

Abstract

Hepatitis is a general term, which refers to the inflammation of the liver. Hepatitis occurs as a result of infection with various pathogens, exposure to alcohol, medications, chemicals, toxins, as well as immune disorders.

Keywords

Fulminant Hepatitis Coxsackie Virus Herpes Simples Virus Herpes Simplex Virus Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Koff RS, Hepatitis A. Lancet. 1998;351:1643–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Brown EA, Stapleton JT. Hepatitis A virus. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of clinical microbiology, Vol. 2. 8th ed. Washington, DC: ASM Press; 2003. p. 1452.Google Scholar
  3. 3.
    Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunisation. MMWR. 2006;55(RR-7):1–23.Google Scholar
  4. 4.
    Curry MP, Chopra S. Acute viral hepatitis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s: principles and practice of infectious diseases, Vol. 1. 6th ed. Philadelphia: Elsevier; 2005. p. 1426.Google Scholar
  5. 5.
    Mohd Hanafiah K, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. Int J Health Geogr. 2011;10:57.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev. 2001;14:38–58.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Bower WA, Nainan OV, Han X, Margolis HS. Duration of viremia in hepatitis A virus infection. J Infect Dis. 2000;182:12–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Jacobsen KH. Hepatitis A virus in West Africa: is an epidemiological transition beginning? Niger Med J. 2014;55(4):279–84.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Maynard JE. Hepatitis B: global importance and need for control. Vaccine. 1990;8(Suppl):S18–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Norder H, Hammas B, Lee SD, Bile K, Courouce AM, Mushahwar IK, et al. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol. 1993;74(7):1341–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat. 2005;12(5):456–64.PubMedCrossRefGoogle Scholar
  13. 13.
    Kew MC, Reis P, Macnab GM. The witch doctor and tribal scarification of the skin and the hepatitis B antigen. S Afr Med J. 1973;47(50):2419–20.PubMedGoogle Scholar
  14. 14.
    Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, Sim J. Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol. 1999;58(2):111–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.PubMedCrossRefGoogle Scholar
  16. 16.
    Burnett RJ, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B vaccination in South Africa. Vaccine. 2012;30(Suppl 3):C45–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Burnett RJ, Ngobeni JM, François G, et al. Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. Int J STD AIDS. 2007;18(3):152–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis. 1994;170(6):1418–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Edmunds WJ, Medley GF, Nokes DJ, O’Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996;117(2):313–25.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003;10(4):294–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16(2):94–103.PubMedCrossRefGoogle Scholar
  22. 22.
    Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA. 2011;305(6):576–84.PubMedCrossRefGoogle Scholar
  23. 23.
    Petrova M, Kamburov V. Breastfeeding and chronic HBV infection: clinical and social implications. World J Gastroenterol. 2010;16(40):5042–6.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat. 2005;12(2):111–24.PubMedCrossRefGoogle Scholar
  25. 25.
    De Schryver AA, Van Hooste W, et al. Managing risk of hepatitis B after sharps injuries. BMJ. 2015;351:h5568.PubMedCrossRefGoogle Scholar
  26. 26.
    Beath SV, Boxall EH, Watson RM, Tarlow MJ, Kelly D. Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers. BMJ. 1992;304:1169–70.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Hawkins AE, Gilson RJC, Beath SV, Boxall EH, Kelly DA, Tedder RS, Weller IVD. Novel application of a point mutation assay: evidence for transmission of hepatitis B virus with precore mutations and their detection in infants with fulminant hepatitis B. J Med Virol. 1994;44:13–21.PubMedCrossRefGoogle Scholar
  28. 28.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.CrossRefGoogle Scholar
  29. 29.
    Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.PubMedCrossRefGoogle Scholar
  30. 30.
    McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45–55.PubMedCrossRefGoogle Scholar
  31. 31.
    Chen CJ, Iloeje UH, Yang H. Long-term outcomes in Hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11:797–816.PubMedCrossRefGoogle Scholar
  32. 32.
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86.Google Scholar
  33. 33.
    Yang H, Lu S, Liaw Y, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–74.PubMedCrossRefGoogle Scholar
  34. 34.
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.PubMedCrossRefGoogle Scholar
  35. 35.
    Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005;79(15):9369–80.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43(2 Suppl 1):S173–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23(1):47–58.PubMedCrossRefGoogle Scholar
  38. 38.
    Giovanna F, Bortolotti F, Francesco D. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.CrossRefGoogle Scholar
  39. 39.
    Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus: a prospective study with long-term observation of 41 patients. Medicine. 1995;74(5):238–53.PubMedCrossRefGoogle Scholar
  40. 40.
    Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. A comprehensive immunisations strategy to eliminate hepatitis B virus transmission in the United States. Part 1: immunisation of infants, children and adolescents. MMWR. 2005;54(RR-16):1–3.PubMedGoogle Scholar
  41. 41.
    Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV co-infection-a global challenge. N Engl J Med. 2012;366:1749.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Matthews PC, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol. 2014;61:20.PubMedCrossRefGoogle Scholar
  43. 43.
    Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis. 2007;7(6):402–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44(1 Suppl):S65–70.PubMedCrossRefGoogle Scholar
  45. 45.
    Mathews G, Bhagani S. The epidemiology and natural history of HIV/HBV and HCV co-infections. J HIV Ther. 2003;8:77–84.PubMedGoogle Scholar
  46. 46.
    Stabinski L, Reynolds SJ, Ocama P, et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther. 2011;16:405–11.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Ibrahim A, Shpaner A, Nieto J. Risk factors of accelerated liver fibrosis in HIV-HCV coinfection: a matched analysis. South Afr Gastroenterol Rev. 2004;2(3):14–7.Google Scholar
  48. 48.
    Mphahlele MJ. Impact of HIV co-infection on hepatitis B prevention and control: a view from Sub-Saharan Africa. South Afr J Epidemiol Infect. 2008;23(1):14–8.Google Scholar
  49. 49.
    Mayaphi SH, Roussow TM, Masemola DP, et al. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. South Afr Med J. 2012;102:157–62.CrossRefGoogle Scholar
  50. 50.
    Thio CL. Hepatitis B and human immunodeficiency virus co-infection. Hepatology. 2009;49(5 Suppl):S138–45.PubMedCrossRefGoogle Scholar
  51. 51.
    Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61(Suppl 1):i47–58.PubMedCrossRefGoogle Scholar
  52. 52.
    Andersson MI, Maponga TG, Ijaz S, et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. Vaccine. 2013;31(47):5579–84.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Thio CL, Seaberg EC, Skolasky Jr R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Puoti M, Spinetti A, Ghezzi AJ, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24(3):211–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19(6):593.PubMedCrossRefGoogle Scholar
  57. 57.
    Kew MC. Hepatocellular carcinoma in African Blacks: recent progress in etiology and pathogenesis. World J Hepatol. 2010;2(2):65–73.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Sonderup MW, Wainwright H, Hall P, Hairwadzi H, Spearman CW. A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome. Hepatology. 2015;61(5):1721–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):1–65.CrossRefGoogle Scholar
  60. 60.
    WHO Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection 2015. www.who.int/mediacentre/news/releases/2015/hepatitis-b-guideline/en/. Accessed 4 Dec 2015.
  61. 61.
    Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.PubMedCrossRefGoogle Scholar
  62. 62.
    WHO 2009 position paper on hepatitis B vaccines. Geneva: World Health Organization; No 40, 2009, 84, 405-420. http://www.who.int/wer.
  63. 63.
    WHO/UNICEF Joint Reporting Form 2014, as at 05 November 2015 and ECDC published data at http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
  64. 64.
    WHO vaccine-preventable diseases: monitoring system. 2016 global summary. http://apps.who.int/immunization_monitoring/globalsummary
  65. 65.
    Chen DS, Hsu NH, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA. 1987;257(19):2597–603.PubMedCrossRefGoogle Scholar
  66. 66.
    Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA. 1988;260(15):2231.PubMedCrossRefGoogle Scholar
  67. 67.
    Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA. 1996;276(11):906–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796–800.PubMedCrossRefGoogle Scholar
  69. 69.
    Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348–55.PubMedCrossRefGoogle Scholar
  71. 71.
    Chien YC, Jan CF, Chiang CJ, et al. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccines. Hepatology. 2014;60(1):125–32.PubMedCrossRefGoogle Scholar
  72. 72.
    Kao JH. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2015;29(6):907–17.PubMedCrossRefGoogle Scholar
  73. 73.
    Wiseman E, Fraser M, Holden S, Glass A, Kidson BL, Heron LG, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190:489–92.PubMedGoogle Scholar
  74. 74.
    Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19:e18–25.PubMedCrossRefGoogle Scholar
  75. 75.
    Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468–76.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Pan CQ, Zou H-B, Chen Y, et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol. 2013;11:1349–55.PubMedCrossRefGoogle Scholar
  77. 77.
    del Canho R, Grosheide PM, Schalm SW, de Vries RR, Heijtink RA. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol. 1994;20:483–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:520–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991;88(6):2451–5.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Davis GL. Hepatitis C virus genotypes and quasispecies. Am J Med. 1999;107(6B):21S–6S.PubMedCrossRefGoogle Scholar
  81. 81.
    Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007;28(5):519–24.PubMedCrossRefGoogle Scholar
  82. 82.
    Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59(6):765–73.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58–68.PubMedCrossRefGoogle Scholar
  84. 84.
    Resti M, Bortolotti F, Vajro P, et al. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. Dig Liver Dis. 2003;35:453–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Resti M, Jara P, Hierro L, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol. 2003;70:373–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Yeung LT, To T, King SM, et al. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat. 2007;14:797–805.PubMedCrossRefGoogle Scholar
  87. 87.
    European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005;41:45–51.CrossRefGoogle Scholar
  88. 88.
    Farmand S, Wirth S, Loffler H, et al. Spontaneous clearance of hepatitis C virus in vertically infected children. Eur J Pediatr. 2012;171:253–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Bortolotti F, Verucchi G, Camma C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008;134:1900–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Casiraghi MA, De PM, Romano L, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004;39:90–6.PubMedCrossRefGoogle Scholar
  91. 91.
    Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999;341:866–70.PubMedCrossRefGoogle Scholar
  92. 92.
    Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood. 1997;90:4628–33.PubMedGoogle Scholar
  93. 93.
    Delgado-Borrego A, Healey D, Negre B, et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2010;51:191–7.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Cesaro S, Bortolotti F, Petris MG, et al. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer. 2010;55:108–12.PubMedGoogle Scholar
  95. 95.
    Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200:1216–26.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Wise M, Finelli L, Sorvillo F. Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data. Public Health Rep. 2010;125:414–22.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Pastore M, Willems M, Cornu C, et al. Role of hepatitis C virus in chronic liver disease occurring after orthotopic liver transplantation. Arch Dis Child. 1995;72:403–7.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005;100(1):48–55.PubMedCrossRefGoogle Scholar
  99. 99.
    Granot E, Sokal EM. Hepatitis C virus in children: deferring treatment in expectation of direct-acting antiviral agents. Isr Med Assoc J. 2015;17(11):707–11.PubMedGoogle Scholar
  100. 100.
    Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology. 2005;41:1013–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Jara P, Hierro L, De la Vega A, et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J. 2008;27:142–8.PubMedGoogle Scholar
  102. 102.
    Sokal EM, Bourgois A, Stephenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol. 2010;52:827–31.PubMedCrossRefGoogle Scholar
  103. 103.
    Balistreri WF, Murray KF, Rosenthal P. The safety and effectiveness of Ledipasvir-Sofosbuvir in adolescents 12 to 17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2016 December 20. [Epub ahead of print].Google Scholar
  104. 104.
    Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85.PubMedCrossRefGoogle Scholar
  105. 105.
    Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18:434–42.PubMedCrossRefGoogle Scholar
  106. 106.
    Heller T, Rotman Y, Koh C, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014;40:93–104.PubMedCrossRefGoogle Scholar
  107. 107.
    Rein DB, Stevens J, Theaker JS, Wittenborn ST, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012;55(4):988–97.PubMedCrossRefGoogle Scholar
  108. 108.
    Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis. 2008;8:698–709.PubMedCrossRefGoogle Scholar
  109. 109.
    Dalton HR, Pas SD, Madden RG, van der Eijk AA. Hepatitis E: current concepts and future perspectives. Curr Infect Dis Rep. 2014;16(4):399.PubMedCrossRefGoogle Scholar
  110. 110.
    Teshale EH, Hu DJ. Hepatitis E: epidemiology and prevention. World J Hepatol. 2011;3(12):285–91.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Teshale EH, Hu DJ, Holmberg SD. The two faces of Hepatitis E. Clin Infect Dis. 2010;51:328–34.PubMedCrossRefGoogle Scholar
  112. 112.
    Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol. 2006;16:5–36.PubMedCrossRefGoogle Scholar
  113. 113.
    Okamoto H. Genetic variability and evolution of hepatitis E virus. Virus Res. 2007;127:216–28.PubMedCrossRefGoogle Scholar
  114. 114.
    Centers for Disease Control and Prevention 2008. http://www.cdc.gov/ncidod/diseases/hepatitis/slideset/hep_e/slide_1.htm. Accessed 8 Dec 2016.
  115. 115.
    Teshale EH, Howard CM, et al. Hepatitis E epidemic, Uganda. Emerg Infect Dis. 2010;16:126–12.PubMedCrossRefGoogle Scholar
  116. 116.
    Sharapov MB, Favorov MO, Yashina TL, et al. Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data. BMC Infect Dis. 2009;9(35):1–9.Google Scholar
  117. 117.
    Khurro MS, Kamil S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat. 2003;10:61–9.Google Scholar
  118. 118.
    Kumar A, Beniwal M, Kar P, Sharma JB, Murthy NS. Hepatitis E in pregnancy. Int J Gynaecol Obstet. 2004;85:240–4.PubMedCrossRefGoogle Scholar
  119. 119.
    Mushahwar IK. Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention. J Med Virol. 2008;80(4):646–58.PubMedCrossRefGoogle Scholar
  120. 120.
    Khurro MS, Rustgi VK, Dawson GJ, et al. Spectrum of hepatitis E virus infection in India. J Med Virol 1994;43:281–86.Google Scholar
  121. 121.
    Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:811–7.PubMedCrossRefGoogle Scholar
  122. 122.
    Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011;140:1481–9.PubMedCrossRefGoogle Scholar
  123. 123.
    Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, Koopmans MP. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2008;14(4):547–53.PubMedCrossRefGoogle Scholar
  124. 124.
    Dalton HR, Bendall R, Keane F, et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361:1025–7.PubMedCrossRefGoogle Scholar
  125. 125.
    Ollier L, Tieulie N, Sanderson F, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med. 2009;150:430–1.PubMedCrossRefGoogle Scholar
  126. 126.
    Norvell JP, Blei AT, Jovanovic BD, Levitsky J. Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl. 2007;13(10):1428–34.PubMedCrossRefGoogle Scholar
  127. 127.
    Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001;108(2):230–8.PubMedCrossRefGoogle Scholar
  128. 128.
    Verma A, Dhawan A, Zuckerman M, Hadzic N, Baker AJ, Mieli-Vergani G. Neonatal herpes simplex virus infection presenting as acute liver failure: prevalent role of herpes simplex virus type I. J Pediatr Gastroenterol Nutr. 2006;42:282–6.PubMedCrossRefGoogle Scholar
  129. 129.
    Egawa H, Inomata Y, Nakayama S, Matsui A, Yamabe H, Uemoto S, et al. Fulminant hepatic failure secondary to herpes simplex virus infection in a neonate: a case report of successful treatment with liver transplantation and perioperative acyclovir. Liver Transpl Surg. 1998;4:513.PubMedCrossRefGoogle Scholar
  130. 130.
    Nakase H, Herfarth H. Cytomegalovirus colitis, cytomegalovirus hepatitis and systemic cytomegalovirus infection: common features and differences. Inflamm Intest Dis. 2016;1:15–23.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Cohen JL. Epstein-Barr virus infection. N Eng J Med. 2000;343:481–92.CrossRefGoogle Scholar
  132. 132.
    Odumade OA, Hogquist KA, Balfour Jr HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011;24:193.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Yuge A, Kinoshita E, Moriuchi M, Ohno Y, Haga H, Moriuchi H. Persistent hepatitis associated with chronic active Epstein–Barr virus infection. Pediatr Infect Dis J. 2004;23:74–6.PubMedCrossRefGoogle Scholar
  134. 134.
    Drebber U, Kasper HU, Krupacz J, et al. The role of Epstein–Barr virus in acute and chronic hepatitis. J Hepatol. 2006;44:879–85.PubMedCrossRefGoogle Scholar
  135. 135.
    Feranchak AP, Tyson RW, Narkewicz MR, Karrer FM, Sokol RJ. Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg. 1998;4:469–76.PubMedCrossRefGoogle Scholar
  136. 136.
    Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis. 1999;31:543.PubMedCrossRefGoogle Scholar
  137. 137.
    Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol. 2010;49(3):151–7.PubMedCrossRefGoogle Scholar
  138. 138.
    Cyran EM, Rowe JM, Bloom RE. Intravenous gammaglobulin treatment for immune thrombocytopenia associated with infectious mononucleosis. Am J Hematol. 1991;38(2):124–9.PubMedCrossRefGoogle Scholar
  139. 139.
    Tebruegge M, Curtis N. Enterovirus infections in neonates. Semin Fetal Neonatal Med. 2009;14(4):222–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • C. Wendy Spearman
    • 1
    Email author
  • Ronalda de Lacy
    • 2
  • Elizabeth Goddard
    • 2
  1. 1.Division of Hepatology, Department of Medicine, Faculty of Health SciencesUniversity of Cape Town and Groote Schuur HospitalCape TownSouth Africa
  2. 2.Division of Paediatric Gastroenterology, Department of Paediatrics and Child Health, Faculty of Health SciencesUniversity of Cape Town and Red Cross War Memorial Children’s HospitalCape TownSouth Africa

Personalised recommendations